Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Prothena Corporation PLC (NASDAQ:PRTA)

67.24
Delayed Data
As of Jul 21
 -0.30 / -0.44%
Today’s Change
40.58
Today|||52-Week Range
69.53
+36.69%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$2.6B

Company Description

Prothena Corp. Plc is a clinical stage biotechnology company, which engages in the discovery, development, and commercialization of novel antibodies. Its antibody-based product candidates target a number of potential indications including AL amyloidosis (NEOD001), Parkinson's disease and related synucleinopathies (PRX002), inflammatory diseases including psoriasis, psoriatic arthritis (PRX003), and ATTR amyloidosis (PRX004). The company was founded on December 20, 2012 and is headquartered in Dun Laoghaire, Ireland.

Contact Information

Prothena Corp. Plc
Adelphi Plaza
Dun Laoghaire Dublin 927
P:(531) 236-2500
Investor Relations:
(650) 837-8535

Employees

Shareholders

Mutual fund holders85.23%
Individual stakeholders8.45%
Other institutional25.55%

Top Executives

Gene G. KinneyPresident, Chief Executive Officer & Director
Tran B. NguyenChief Financial Officer
Wagner ZagoChief Scientific Officer
Sarah NoonbergChief Medical Officer
Tara NickersonChief Business Officer